Boost for thyroid cancer treatment

Improved treatments could cut radiation doses experienced by patients with thyroid cancer by two thirds, British researchers reported last night.

Patients are treated with capsules of radioactive iodine and the researchers at University College London have shown that the dose can be reduced substantially.

They say this mainly is because of improved surgical techniques which mean more of the diseased thyroid gland is removed by the surgery.

The reduced doses mean patients can be treated as out-patients and sent home after a few hours – experienced many fewer side-effects than in the past, the researchers reported in the New England Journal of Medicine.

Researchers also found that patients did not need to stop taking thyroid replacement tablets before treatment – and can also be given an injection of a thyroid stimulating hormone.

The thyroid tablets are taken to replace the hormones released by the gland and help people avoid fatigue and weight gain caused by the surgery.

Researcher Dr Ujjal Mallick, who is based at the Freeman Hospital in Newcastle, said: “We’re delighted that this study of thyroid cancer will change international approaches to treat the disease more safely, by reducing the chance of another cancer developing later in life and other side effects.

“Patients will have a much better quality of life. They’ll be treated much more quickly, which will keep the disruption to their lives to a minimum, as well as saving the NHS money.”

The research involved some 438 patients across the UK, including a medical student from Newcastle.

The student Amy Horton, aged 24, from Scarborough, said: "I was lucky to be on the trial and I received the lower dose. Thankfully I didn’t experience too many side effects and was able to return to my studies almost straight away.

“It was great not to have to stay at hospital or spend a long time feeling really unwell and I’m very pleased I could be part of research that means that future patients will now all have this quicker and safer treatment.”

Kate Law, director of clinical research at Cancer Research UK, said the research was "pivotal".

She said: “Being treated as an outpatient means that patients should be able to be in their home surroundings on the same day as the treatment."

Low-dose radioiodine and thyrotropin alfa for thyroid cancer. The New England Journal of Medicine May 2 2012

,

Leave a Reply

Your email address will not be published. Required fields are marked *

Search

Categories

Monthly Posts

Our Clients

BSH
Practice Index